Maier 1985.
Study characteristics | ||
Methods | Randomized controlled trial | |
Participants | People with active inflammatory bowel disease (ulcerative colitis n = 30, or Crohn's disease n = 30) | |
Interventions | Oral 5‐ASA, 0.5 g 3 times daily (n = 15) or oral SASP, 1.0 g 3 times daily (n = 15) for 8 weeks | |
Outcomes | Remission and clinical improvement | |
Notes | Study also enrolled 30 participants with Crohn's disease Funding support and conflicts of interest were not reported |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Not described |
Allocation concealment (selection bias) | Unclear risk | Not described |
Blinding (performance bias and detection bias) All outcomes | Unclear risk | Not described |
Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Not described |
Selective reporting (reporting bias) | Unclear risk | Not described |
Other bias | Unclear risk | Not described |